Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome.
Biomarkers
Cardiovascular risk factors
Coronary heart disease
Sleep disorders
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
received:
07
07
2023
revised:
20
09
2023
accepted:
22
09
2023
medline:
4
12
2023
pubmed:
26
9
2023
entrez:
25
9
2023
Statut:
ppublish
Résumé
Sleep-related breathing disorders (SRBD) are related to cardiovascular outcomes in patients with chronic coronary syndrome (CCS). Whether SRBD-related symptoms are associated with prognostic biomarkers in patients with CCS is not established. Associations between frequency (never/rarely, sometimes, often, always) of self-reported SRBD-related symptoms (excessive daytime sleepiness [EDS]; morning tiredness [MT]; loud snoring; multiple awakenings/night; gasping, choking, or apnea when asleep) and levels of biomarkers related to cardiovascular prognosis (high-sensitivity C-reactive protein [hs-CRP], interleukin 6 [IL-6], high-sensitivity cardiac troponin T [hs-cTnT], N-terminal pro B-type natriuretic peptide [NT-proBNP], cystatin C, growth differentiation factor 15 [GDF-15] and lipoprotein-associated phospholipase A EDS was associated (geometric mean ratio, 95% confidence interval) with increased levels of IL-6 (often 1.07 [1.03-1.10], always 1.15 [1.10-1.21]), GDF-15 (often 1.03 [1.01-1.06], always 1.07 [1.03-1.11]), NT-proBNP (always 1.22 [1.12-1.33]), and hs-cTnT (always 1.07 [1.01-1.12]). MT was associated with increased levels of IL-6 (often 1.05 [1.01-1.09], always 1.09 [1.04-1.15]), and GDF-15 (always 1.06 [1.03-1.10]). All symptoms were to some degree associated with higher levels of hs-CRP and loud snoring was also associated with decreased levels of NT-proBNP and hs-cTnT. In patients with CCS, stepwise increased frequency of SRBD-related symptoms, such as EDS and MT, were associated with gradually higher levels of IL-6 and GDF-15, each reflecting distinct pathophysiological pathways.
Sections du résumé
BACKGROUND
BACKGROUND
Sleep-related breathing disorders (SRBD) are related to cardiovascular outcomes in patients with chronic coronary syndrome (CCS). Whether SRBD-related symptoms are associated with prognostic biomarkers in patients with CCS is not established.
METHODS
METHODS
Associations between frequency (never/rarely, sometimes, often, always) of self-reported SRBD-related symptoms (excessive daytime sleepiness [EDS]; morning tiredness [MT]; loud snoring; multiple awakenings/night; gasping, choking, or apnea when asleep) and levels of biomarkers related to cardiovascular prognosis (high-sensitivity C-reactive protein [hs-CRP], interleukin 6 [IL-6], high-sensitivity cardiac troponin T [hs-cTnT], N-terminal pro B-type natriuretic peptide [NT-proBNP], cystatin C, growth differentiation factor 15 [GDF-15] and lipoprotein-associated phospholipase A
RESULTS
RESULTS
EDS was associated (geometric mean ratio, 95% confidence interval) with increased levels of IL-6 (often 1.07 [1.03-1.10], always 1.15 [1.10-1.21]), GDF-15 (often 1.03 [1.01-1.06], always 1.07 [1.03-1.11]), NT-proBNP (always 1.22 [1.12-1.33]), and hs-cTnT (always 1.07 [1.01-1.12]). MT was associated with increased levels of IL-6 (often 1.05 [1.01-1.09], always 1.09 [1.04-1.15]), and GDF-15 (always 1.06 [1.03-1.10]). All symptoms were to some degree associated with higher levels of hs-CRP and loud snoring was also associated with decreased levels of NT-proBNP and hs-cTnT.
CONCLUSIONS
CONCLUSIONS
In patients with CCS, stepwise increased frequency of SRBD-related symptoms, such as EDS and MT, were associated with gradually higher levels of IL-6 and GDF-15, each reflecting distinct pathophysiological pathways.
Identifiants
pubmed: 37748524
pii: S0167-5273(23)01388-8
doi: 10.1016/j.ijcard.2023.131395
pii:
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Growth Differentiation Factor 15
0
Interleukin-6
0
Biomarkers
0
Natriuretic Peptide, Brain
114471-18-0
Peptide Fragments
0
Troponin T
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
131395Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest MO: institutional research grants from GlaxoSmithKline. EH: research grants and speaker fees from Amgen, Sanofi; expert committee fees from NovoNordisk. NH: institutional research grant from GlaxoSmithKline. ML, SD, and AM: no conflict of interest. LW: institutional research grants from AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Merck&Co, Roche Diagnostics, Boehringer Ingelheim; consulting fees from Abbott; holds two patents involving GDF-15, both licensed to Roche Diagnostics. HDW: research grants from GlaxoSmithKline; grants and steering committee fees from Eli Lilly and Company, Omthera Pharmaceuticals, Eisai Inc., Dalcor Pharma UK, American Regent; grants and steering committee and advisory board fees from CSL Behring LLC; grants, steering committee, and personal fees from Sanofi-Aventis Australia Pty Ltd., Esperion Therapeutics Inc., Sanofi-Aventis; advisory board fees from Genentech, Inc.; personal fees from AstraZeneca. RAHS: research grants from GlaxoSmithKline. CH: honoraria from Pfizer; consultant and advisory board fees from AstraZeneca, Bayer, Boehringer Ingelheim.